Targeting BCL-2 in leukemia:
We utilize state-of-the-art technique BH3 profiling to measure apoptotic sensitivity and anti-apoptotic dependencies of cancer to identify targeted therapeutic treatments.
Identifying Novel Therapeutics for Chemoresistant Breast Cancer:
We performed high-throughput screening onover 30,000 small molecule to identify targeted therapeutics that kill chemoresistant cancer cells but that do not kill “normal” non-transformed cells. Using advanced proteomic approaches we are determining mechanism of action of these novel compounds